Target Audience:

This activity has been designed to meet the educational needs of gastroenterologists and other healthcare providers involved in the care of patients with Congenital Sucrase-Isomaltase Deficiency (CSID).

Educational Objectives:

After completing this program, participants should be better able to:

  • Describe the role of intestinal disaccharidases in health and disease.
  • Summarize recent evidence regarding the epidemiology, presentation, and natural history of patients with CSID.
  • Incorporate practical screening/diagnostic strategies to identify appropriates patients for screening, interpret test results accurately, and effectively differentiate CSID from other common GI disordered seen in clinical practice.
  • Describe the role of dietary modification and enzyme supplementation in the management of patients with CSID.

Accreditation Statement and Credit Designation:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS) and the Gi Health Foundation (GIHF). RMCHCS is accredited by the NMMS to provide continuing medical education for physicians.

RMCHCS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accredited by

Provided by

Supported by an educational grant from QOL Medical LLC.

This event is neither sponsored nor endorsed by ACG.

JOIN THE DISCUSSION AT OUR VIRTUAL CME SYMPOSIUM!

RETHINKING CSID:

TIME FOR A PARADIGM SHIFT?

Saturday, October 24, 2020

4:15 – 5:45 PM ET / 3:15 – 4:45 PM CT /
2:15 – 3:45 PM MT / 1:15 – 2:45 PM PT

FEATURED FACULTY

(Select a faculty member to view their disclosures)

AGENDA

4:15 PM

Introduction and Late-Breaking News

4:25 PM

When IBS Is Not IBS:
Rare Causes of Unexplained Diarrhea

4:45 PM

Intestinal Disaccharidases:
Role in Health and Disease

5:10 PM

Sucrase Isomaltase Deficiency:
Clinical Presentations, Diagnosis, and Treatment

5:35 PM

Panel Discussion and Q&A

5:45 PM

Closing Remarks

WILLIAM D. CHEY, MD, AGAF, FACG, FACP (CHAIR)

Timothy T. Nostrant Collegiate Professor of Gastroenterology
Director, GI Physiology Laboratory
Director, Digestive Disorders Nutrition & Behavioral Health Program
Director, Michigan Food for Life Kitchen
Medical Director, Michigan Bowel Control Program
Division of Gastroenterology
Departments of Internal Medicine and Nutritional Sciences
Michigan Medicine
Ann Arbor, Michigan

Dr. Chey received his BA degree from the University of Pennsylvania and medical degree & training in internal medicine at Emory University School of Medicine. He completed a fellowship in gastroenterology and has remained as faculty at the University of Michigan in Ann Arbor where he is currently the Timothy T. Nostrant Collegiate Professor of Gastroenterology. He was awarded a joint appointment in the Department of Nutrition Sciences in 2015.

His research interests focus on the diagnosis and treatment of functional bowel disorders, acid-related disorders, and H. pylori infection. He is a medical innovator and holds three patents. He co-founded My Total Health (https://mygihealth.io/), a company developing novel health information technology solutions for persons with GI problems.

Dr. Chey has authored more than 300 manuscripts, reviews, chapters, and books. He served as Co-Editor-in-Chief of the American Journal of Gastroenterology (2010– 2015) and Founding Co-Editor of Clinical & Translational Gastroenterology (2011–2014). He also led the ACG H. pylori practice guideline published in the American Journal of Gastroenterology in 2017. He served on the Editorial Board for the Rome IV criteria for functional GI disorders published in 2016. He is a member of the ACG IBS Task Force responsible for an evidence-based monograph published in 2018. He is working with the ACG, the AGA, and the CAG on three additional clinical practice guidelines.

Dr. Chey is a member of the Board of Trustees of the American College of Gastroenterology, the Board of Directors of the Rome Foundation, and the Council of the American Neurogastroenterology and Motility Society. He is Scientific Advisor for the International Foundation of Functional GI Disorders.

He has been elected to Best Doctors since 2001 and America's Top Doctors since 2009, and he has repeatedly been named as one of the Top Gastroenterologists in Detroit. He has received the Dean’s Outstanding Clinician Award and the Dean’s Award for Innovation and Commercialization at the University of Michigan as well as the Distinguished Clinician Award from the American Gastroenterological Association. He has previously served as President of the Clinical Excellence Society in the Department of Medicine at Michigan Medicine.

SPEAKER DISCLOSURES:

Honorarium: Alnylam Pharmaceuticals, Avena, Biomerica, IM Health, Ironwood, Allakos, Cosmo Pharmaceuticals, Gemelli, QOL Medical LLC, Projenity, RedHill Biopharma, Salix, Takeda, and Vibrant Pharmaceuticals.

BROOKS D. CASH, MD, FACG

Dan and Lillie Sterling Professor of Medicine
Chief, Gastroenterology, Hepatology, and Nutrition
UT Health Science Center at Houston
Houston, Texas

Brooks D. Cash, MD, is the Chief of the Gastroenterology Division at the UT Health Science Center and the Co Director of the Ertan Digestive Disease Center at Memorial Herman. He holds the rank of Professor of Medicine at UT McGovern Medical School as well as the rank of Professor of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, MD. He is board-certified in gastroenterology, and his professional excellence has resulted in his election to fellowship in the American College of Physicians, the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy. Dr. Cash served for 24 years in the US Navy before retiring in 2013 with the rank of Navy Captain. While in the Navy, he served as Chief of Gastroenterology, Chief of Medicine, and Deputy Commander for Medicine at the Bethesda Naval Hospital and the Walter Reed Army Medical Center. In his clinical duties, he served as Gastroenterology Consultant to the US Navy Surgeon General, Attending Physician to Congress, and the White House Medical Unit . Prior to joining UT in 2018, he was the Chief of Gastroenterology at the University of South Alabama in Mobile, AL. As a recognized international expert in the field of irritable bowel syndrome and other functional gastrointestinal disorders, he has chaired numerous professional society committees and meetings.

Dr. Cash has served on the Rome Committee for Functional Gastrointestinal Disorders and has authored over 200 articles and book chapters on a wide variety of gastrointestinal topics, including irritable bowel syndrome, chronic constipation, opioid-induced constipation, colorectal cancer screening, CT colonography, gastroesophageal reflux disease, Barrett’s esophagus, medical education techniques, and evidence-based medicine. He is active in clinical research and education, serving as an associate editor for the American Journal of Gastroenterology as well as an editorial board member and reviewer for multiple internal medicine and gastroenterology medical journals. He is also a highly sought-after lecturer at national and international scientific meetings.

SPEAKER DISCLOSURES:

Speaker: QOL Medical LLC
Honorarium: QOL Medical LLC

ANTHONY LEMBO, MD

Professor of Medicine, Harvard Medical School
Director, GI Motility and Functional Bowel Disorders Program at
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Anthony J. Lembo, MD, is a Professor of Medicine at Harvard Medical School. He also serves as the Director of the GI Motility Laboratory at the Beth Israel Deaconess Medical Center (BIDMC) Division of Gastroenterology in Boston, MA. Dr. Lembo earned his undergraduate degree in mathematics at Amherst College in Amherst, MA, and then received his MD from Tufts Medical School in Boston, MA. He subsequently completed his internal medicine internship/residency as well as his gastroenterology fellowship at the UCLA Medical Center in Los Angeles, CA. After completing these programs, Dr. Lembo became a Clinical Instructor of Medicine at UCLA in 1996 and served as the Co-Director of the FBD and GI Motility Center at the UCLA Medical Center. While at UCLA, Dr. Lembo conducted research on functional bowel disorders. In 1997, he joined the faculty at the BIDMC in Boston, MA. He is currently the Director of the GI Motility and Functional Bowel Disorder Center at the BIDMC and the Co-Director of the GI Motility Laboratory. He is an associate editor of the Journal of Clinical Gastroenterology and Digestive Diseases and Science. His research has focused on the development of novel treatments for functional bowel disorders, including chronic idiopathic constipation. His research has also explored the roles of placebos and methods of enhancing the placebo response.

SPEAKER DISCLOSURES:

Honorarium: AbbVie, Allegan, Bayer, Ironwood, Mylan, QOL Medical LLC, RedHill, Shire, and Takeda.

DAKSESH B. PATEL, DO

Illinois Gastroenterology Group/Gi Alliance
Chief, Division of Gastroenterology and Hepatology
AMITA St. Francis Hospital
Evanston, IL

Dr. Patel completed his gastroenterology and hepatology fellowship in Michigan at St. John Providence Health System and pursued additional training during an Advanced Therapeutics Fellowship at Rush University Medical Center in Chicago. He currently serves as Division Chief of Gastroenterology at St. Francis Hospital in Evanston, IL and is passionate about CSID. He has lectured extensively on the topic and most recently was involved in formulating the CSID monograph included in the October publication of Gastroenterology and Hepatology. He is a partner within the GI Alliance and is embarking on conducting a large-scale study through the GI Health Foundation aimed to better define the prevalence of CSID amongst an adult IBS cohort and to determine the validity of sucrose breath tests utilized in the diagnosis of CSID.

SPEAKER DISCLOSURES:

Speaker: QOL Medical LLC
Honorarium: QOL Medical LLC